rs1439287
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_001142807.4(ACOXL):c.1543-3296G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.419 in 152,256 control chromosomes in the GnomAD database, including 13,875 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.42 ( 13839 hom., cov: 32)
Exomes 𝑓: 0.51 ( 36 hom. )
Consequence
ACOXL
NM_001142807.4 intron
NM_001142807.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.228
Publications
32 publications found
Genes affected
ACOXL (HGNC:25621): (acyl-CoA oxidase like) Predicted to enable acyl-CoA oxidase activity; fatty acid binding activity; and flavin adenine dinucleotide binding activity. Predicted to be involved in fatty acid beta-oxidation using acyl-CoA oxidase and lipid homeostasis. Predicted to be located in peroxisomal matrix. Predicted to be active in peroxisome. [provided by Alliance of Genome Resources, Apr 2022]
ACOXL-AS1 (HGNC:41112): (ACOXL antisense RNA 1)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.92).
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.471 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.419 AC: 63588AN: 151832Hom.: 13840 Cov.: 32 show subpopulations
GnomAD3 genomes
AF:
AC:
63588
AN:
151832
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.513 AC: 157AN: 306Hom.: 36 Cov.: 0 AF XY: 0.546 AC XY: 107AN XY: 196 show subpopulations
GnomAD4 exome
AF:
AC:
157
AN:
306
Hom.:
Cov.:
0
AF XY:
AC XY:
107
AN XY:
196
show subpopulations
African (AFR)
AC:
0
AN:
0
American (AMR)
AC:
0
AN:
0
Ashkenazi Jewish (ASJ)
AC:
0
AN:
0
East Asian (EAS)
AC:
0
AN:
0
South Asian (SAS)
AC:
0
AN:
0
European-Finnish (FIN)
AF:
AC:
145
AN:
278
Middle Eastern (MID)
AF:
AC:
0
AN:
2
European-Non Finnish (NFE)
AF:
AC:
10
AN:
22
Other (OTH)
AF:
AC:
2
AN:
4
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
5
10
16
21
26
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome AF: 0.419 AC: 63605AN: 151950Hom.: 13839 Cov.: 32 AF XY: 0.413 AC XY: 30668AN XY: 74266 show subpopulations
GnomAD4 genome
AF:
AC:
63605
AN:
151950
Hom.:
Cov.:
32
AF XY:
AC XY:
30668
AN XY:
74266
show subpopulations
African (AFR)
AF:
AC:
15710
AN:
41412
American (AMR)
AF:
AC:
4385
AN:
15270
Ashkenazi Jewish (ASJ)
AF:
AC:
1274
AN:
3470
East Asian (EAS)
AF:
AC:
2206
AN:
5150
South Asian (SAS)
AF:
AC:
1053
AN:
4826
European-Finnish (FIN)
AF:
AC:
5358
AN:
10550
Middle Eastern (MID)
AF:
AC:
69
AN:
294
European-Non Finnish (NFE)
AF:
AC:
32328
AN:
67960
Other (OTH)
AF:
AC:
815
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1867
3734
5600
7467
9334
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
598
1196
1794
2392
2990
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1098
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.